Log in

6872 TenNor Therapeutics Suzhou Ltd. HKEX · China

TenNor Therapeutics Suzhou (6872) news

TenNor Therapeutics Suzhou Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6872, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest TenNor Therapeutics Suzhou news

We have not published a story on TenNor Therapeutics Suzhou yet. When there is news, it will appear here.

Questions about TenNor Therapeutics Suzhou

What is the ticker symbol of TenNor Therapeutics Suzhou?

TenNor Therapeutics Suzhou Ltd. trades under the ticker 6872 on HKEX.

Where is TenNor Therapeutics Suzhou listed?

TenNor Therapeutics Suzhou Ltd. is listed on HKEX.

Which country or territory is TenNor Therapeutics Suzhou listed under?

Our directory records TenNor Therapeutics Suzhou Ltd. under China.

What does TenNor Therapeutics Suzhou do?

Our directory classifies TenNor Therapeutics Suzhou Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of TenNor Therapeutics Suzhou?

The ISIN recorded for TenNor Therapeutics Suzhou Ltd. is CNE100007KG6.

Does aibio.space cover TenNor Therapeutics Suzhou?

aibio.space lists TenNor Therapeutics Suzhou Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to TenNor Therapeutics Suzhou?

Companies in our directory listed in the same country and business area as TenNor Therapeutics Suzhou: Hanx Biopharmaceuticals (Wuhan) Co., PegBio Co., Sichuan Kelun Pharmaceutical Co., JW (Cayman) Therapeutics Co., Beijing Tiantan Biological Products Corporation, Shouyao Holdings Beijing Co..

Investor discussion: TenNor Therapeutics Suzhou

Members talk about TenNor Therapeutics Suzhou (6872). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at TenNor Therapeutics Suzhou, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: CIRCULAR OF 2026 SECOND EXTRAORDINARY GENERAL MEETING. Source

  2. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of TenNor Therapeutics Suzhou's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT H SHARE REPURCHASE PLAN

  2. HKEXnews

    Articles of Association

  3. HKEXnews

    POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, OCTOBER 23, 2026 AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE MULTI-CENTER PHASE IIB CLINICAL TRIAL OF RIFAQUIZINONE (TNP-2092) ADMINISTERED VIA INTRA-ARTICULAR INJECTION FOR THE TREATMENT OF PROSTHETIC JOINT INFECTION

  5. HKEXnews

    NOTICE OF 2026 SECOND EXTRAORDINARY GENERAL MEETING

  6. HKEXnews

    CIRCULAR OF 2026 SECOND EXTRAORDINARY GENERAL MEETING

  7. HKEXnews

    (1) FORMULATION OF THE 2026 H SHARE AWARD SCHEME; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT POSITIVE RESULTS FROM A PHASE IIA PROOF-OF-CONCEPT CLINICAL TRIAL OF RIFAQUIZINONE (TNP-2092) FOR THE TREATMENT OF PROSTHETIC JOINT INFECTION AND INITIATION OF A MULTI-CENTER PHASE IIB CLINICAL TRIAL

  9. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

  10. HKEXnews

    POLL RESULTS OF THE ANNUAL SHAREHOLDERS' MEETING HELD ON MONDAY, JUNE 29, 2026

  11. HKEXnews

    NOTICE OF ANNUAL SHAREHOLDERS' MEETING

  12. HKEXnews

    CIRCULAR OF ANNUAL SHAREHOLDERS' MEETING

  13. HKEXnews

    (1) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (2) NO DISTRIBUTION OF FINAL DIVIDENDS; AND (3) CHANGES IN COMPOSITION OF SPECIAL COMMITTEE UNDER THE BOARD

  14. HKEXnews

    Letter to Non-Registered Holders - Arrangement of Electronic Dissemination of Corporate Communications

  15. HKEXnews

    Letter to Registered Shareholders - Arrangements on Electronic Dissemination of Corporate Communications

  16. HKEXnews

    RESIGNATION OF NON-EXECUTIVE DIRECTOR

  17. HKEXnews

    ANNOUNCEMENT OF ALLOTMENT RESULTS

  18. HKEXnews

    Terms of Reference for the Nomination Committee of the Board of Directors

  19. HKEXnews

    Terms of Reference for the Remuneration and Appraisal Committee of the Board of Directors

  20. HKEXnews

    Terms of Reference for the Audit Committee of the Board of Directors

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6872 on TradingView.

Listing details

TenNor Therapeutics Suzhou Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6872, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
TenNor Therapeutics Suzhou Ltd.
Ticker
6872
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100007KG6
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.